# US 2025/0082606 A1 · Antibacterial compounds, pharmaceutical compositions, and methods of treating bacterial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082606 A1
- Document ID: US20250082606A1
- Status: Published application
- Kind: A1
- Application number: 18/828,686
- Filed: 2024-09-09
- Published: 2025-03-13
- Earliest claimed: 2023-09-11
- Assignees: Miralogx LLC
- Applicants: Miralogx LLC
- Inventors: Jonnie R. Williams, SR.
- Web page: https://patentgrep.com/patent/US20250082606A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/429: condensed with heterocyclic ring systems
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 277/62: Benzothiazoles
- C07D 487/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions containing the compound(s) may be used to treat bacterial infections, such as urinary tract infections, and/or disorders associated with chronic inflammation.

## Claims

### Claim 1

A compound having a structure of Formula (I):
wherein R1, R2, R3, and R4 are each independently selected from the group consisting of an electron pair, H, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, phenyl, carbonate ester, a carboxylate, a carboxyl, an ester, a hydroperoxy, a peroxy, an ether, a hemiacetal, a hemiketal, an acetal, a ketal, an orthoester, a methylenedioxy, an orthocarbonate ester, carboxamide, an amine, an imine, an amide, an azide, an azo, a cyanate, a nitrate, a nitrile, an isonitrile, a nitrosooxy, a nitro, a pyridyl, a thiol, a sulfide, sulfinyl, a sulfonyl, a thiocyanate, a carbonothioyl, a phosphate, and heterocycle; optionally wherein the alkyl, alkenyl, alkynyl or acyl is substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle; wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl; wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl; wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl; wherein X is C or S; or a pharmaceutically acceptable salt or ester thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 and R2 form a ring structure.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound has a structure according to Formula (II):
wherein R3, R4, R5, and R6 are each independently selected from the group consisting of an electron pair, H, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, phenyl, carbonate ester, a carboxylate, a carboxyl, an ester, a hydroperoxy, a peroxy, an ether, a hemiacetal, a hemiketal, an acetal, a ketal, an orthoester, a methylenedioxy, an orthocarbonate ester, carboxamide, an amine, an imine, an amide, an azide, an azo, a cyanate, a nitrate, a nitrile, an isonitrile, a nitrosooxy, a nitro, a pyridyl, a thiol, a sulfide, sulfinyl, a sulfonyl, a thiocyanate, a carbonothioyl, a phosphate, and heterocycle; optionally wherein the alkyl, alkenyl, alkynyl or acyl is substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle; wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl; wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl; wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl; wherein X is C or S; or a pharmaceutically acceptable salt or ester thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein X is C.

### Claim 5 (depends on 1)

The compound of claim 1, wherein X is S.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, or solvate thereof.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable vehicle therefor.

### Claim 9 (depends on 8)

A method of treating a bacterial infection comprising administering to an individual in need thereof the pharmaceutical composition of claim 8.

### Claim 10 (depends on 9)

The method of claim 9 wherein the bacterial infection is a urinary tract infection.
